|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions显示文摘Liver cancers are the second most frequent cause of global cancer-related mortality of which 90%are attributable to hepatocellular carcinoma(HCC).Despite the advent of screening programmes for patients with known risk factors,a substantial number of patients are ineligible for curative surgery at presentation with limited outcomes achievable with systemic chemotherapy/external radiotherapy.This has led to the advent of numerous minimally invasive options including but not limited to trans-arterial chemoembolization,radiofrequency/microwave ablation and more recently selective internal radiation therapy many of which are often the first-line treatment for select stages of HCC or serve as a conduit to liver transplant.The authors aim to provide a comprehensive overview of these various image guided minimally invasive therapies with a brief focus on the technical aspects accompanied by a critical analysis of the literature to assess the most up-to-date evidence from comparative systematic reviews and meta-analyses finishing with an assessment of novel combination regimens and future directions of travel. | Riccardo Inchingolo Alessandro Posa Martin Mariappan Stavros Spiliopoulos | 2019 | World Journal of Gastroenterology2019，25，32： | 14 |
| 2 | Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease:Mechanisms,evaluation and clinical implications显示文摘Antiplatelet therapy with aspirin or clopidogrel or both is the standard care for patients with proven coronary or peripheral arterial disease,especially those undergoing endovascular revascularization procedures. However,despite the administration of the antiplatelet regiments,some patients still experience recurrent cardiovascular ischemic events. So far,it is well documented by several studies that in vitro response of platelets may be extremely variable. Poor antiplatelet effect of clopidogrel or high on-treatment platelet reactivity(HTPR) is under investigation by numerous recent studies. This review article focuses on methods used for the ex vivo evaluation of HTPR,as well as on the possible underlying mechanisms and the clinical consequences of this entity. Alternative therapeutic options and future directions are also addressed. | Stavros Spiliopoulos Georgios Pastromas | 2015 | World Journal of Cardiology2015，7，12： | 13 |
| 3 | Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome:A comprehensive review显示文摘Budd-Chiari syndrome(BCS)is a relatively rare clinical condition with a wide range of symptomatology,caused by the obstruction of the hepatic venous outflow.If left untreated,it has got an high mortality rate.Its management is based on a step-wise approach,depending on the clinical presentation,and includes different treatment from anticoagulation therapy up to Interventional Radiology techniques,such as transjugular intrahepatic portosystemic shunt(TIPS).TIPS is today considered a safe and highly effective treatment and should be recommended for BCS patients,including those awaiting orthotopic liver transplantation.In this review the pathophysiology,diagnosis and treatment options of BCS are presented,with a special focus on published data regarding the techniques and outcomes of TIPS for the treatment of BCS.Moreover,unresolved issues and future research will be discussed. | Riccardo Inchingolo Alessandro Posa Martin Mariappan Tiago Kojun Tibana Thiago Franchi Nunes Stavros Spiliopoulos Elias Brountzos | 2020 | World Journal of Gastroenterology2020，26，34： | 5 |
| 4 | Non-surgical treatment of hilar cholangiocarcinoma显示文摘Cancer of the biliary confluence also known as hilar cholangiocarcinoma(HC)or Klatskin tumor,is a rare type of neoplastic disease constituting approximately 40%-60%of intrahepatic malignancies,and 2% of all cancers.The prognosis is extremely poor and the majority of Klatskin tumors are deemed unresectable upon diagnosis.Most patients with unresectable bile duct cancer die within the first year after diagnosis,due to hepatic failure,and/or infectious complications secondary to biliary obstruction.Curative treatments include surgical resection and liver transplantation in highly selected patients.Nevertheless,very few patients are eligible for surgery or transplant at the time of diagnosis.For patients with unresectable HC,radiotherapy,chemotherapy,photodynamic therapy,and liver-directed minimally invasive procedures such as percutaneous image-guided ablation and intra-arterial chemoembolization are recommended treatment options.This review focuses on currently available treatment options for unresectable HC and discusses future perspectives that could optimize outcomes. | Riccardo Inchingolo Fabrizio Acquafredda Valentina Ferraro Letizia Laera Gianmarco Surico Alessia Surgo Alba Fiorentino Stefania Marini Nicola de'Angelis Riccardo Memeo Stavros Spiliopoulos | 2021 | World Journal of Gastrointestinal Oncology2021，13，11： | 5 |
| 5 | Percutaneous trans-hepatic bilateral biliary stenting in Bismuth Ⅳ malignant obstruction显示文摘AIM: To investigate the clinical efficiency of percutaneous trans-hepatic bilateral biliary metallic stenting for the management of Bismuth Ⅳ malignant obstructive disease. METHODS: Our hospital's database was searched for all patients suffering from the inoperable malignant biliary obstruction Bismuth Ⅳ, and treated with percutaneous bilateral trans-hepatic placement of selfexpandable nitinol stents. The indication for percutaneous stenting was an inoperable, malignant, symptomatic, biliary obstruction. An un-correctable coagulation disorder was the only absolute contra-indication for treatment. Bismuth grading was performed using magnetic resonance cholangiopancreatography. Computed tomography evaluation of the lesion and the dilatation status of the biliary tree was always performed prior to the procedure. All procedures were performed under conscious sedation. A single trans-hepatic track technique was preferred (T-configuration stenting) and a second, contra-lateral trans-hepatic track (Y-configuration stenting) was used only in cases of inability to access the contra-lateral lobe using a single track technique. The study's primary endpoints were clinical success, defined as a decrease in bilirubin levels within 10 d and patient survival rates. Secondary endpoints included peri-procedural complications, primary and secondary patency rates. RESULTS: A total of 35 patients (18 female, 51.4%) with a mean age 69 ± 13 years (range 33-88) were included in the study. The procedures were performed between March 2000 and June 2008 and mean time follow-up was 13.5 ± 22.0 mo (range 0-96). The underlying malignant disease was cholangiocarcinoma (n = 10), hepatocellular carcinoma (n = 9), pancreatic carcinoma (n = 5), gastric cancer (n = 2), bile duct tumor (n = 2), colorectal cancer (n = 2), gallbladder carcinoma (n = 2), lung cancer (n = 1), breast cancer (n = 1) or non-Hodgkin lymphoma (n = 1). In all cases, various self-expandable bare metal stents with diameters ranging from 7 to 10 mm were used. Stents were placed in Y-configuration in 24/35 cases (68.6%) using two stents in 12/24 patients and three stents in 12/24 cases (50%). A T-configuration stent placement was performed in 11/35 patients (31.4%), using two stents in 4/11 cases (36.4%) and three stents in 7/11 cases (63.6%). Follow-up was available in all patients (35/35). Patient survival ranged from 0 to 1763 d and the mean survival time was 168 d. Clinical success rate was 77.1% (27/35 cases), and peri-procedural mortality rate was 5.7% (2/35 patients). Biliary reobstruction due to stent occlusion occurred in 25.7% of the cases (9/35 patients), while in 7/11 (63.6%) one additional percutaneous re-intervention due to stent occlusion resulting in clinical relapse of symptomatology was successfully performed. In the remaining 4/11 patients (36.4%) more than 1 additional reintervention was performed. The median decrease of total serum bilirubin was 60.5% and occurred in 81.8% of the cases (27/33 patients). The median primary and secondary patency was 105 (range 0-719) and 181 d (range 5-1763), respectively. According to the KaplanMeyer survival analysis, the estimated survival rate was 73.5%, 47.1% and 26.1% at 1, 6 and 12 mo respectively, while the 8-year survival rate was 4.9%. Major and minor complication rates were 5.7% (2/35 patients) and 17.1% (6/35 patients), respectively. CONCLUSION: Percutaneous bilateral biliary stenting is a safe and clinically effective palliative approach in patients suffering from Bismuth Ⅳ malignant obstruction. | Dimitrios Karnabatidis Stavros Spiliopoulos Paraskevi Katsakiori Odissefs Romanos Konstantinos Katsanos Dimitrios Siablis | 2013 | World Journal of Hepatology2013，5，3： | 4 |
| 6 | Irreversible electroporation for the management of pancreatic cancer: Current data and future directions显示文摘Pancreatic cancer is currently the seventh leading cause of cancer death(4.5%of all cancer deaths)while 80%-90%of the patients suffer from unresectable disease at the time of diagnosis.Prognosis remains poor,with a mean survival up to 15 mo following systemic chemotherapy.Loco-regional thermal ablative techniques are rarely implemented due to the increased risk of thermal injury to the adjacent structures,which can lead to severe adverse events.Irreversible electroporation,a promising novel non-thermal ablative modality,has been recently introduced in clinical practice for the management of inoperable pancreatic cancer as a safer and more effective loco-regional treatment option.Experimental and initial clinical data are optimistic.This review will focus on the basic principles of IRE technology,currently available data,and future directions. | Stavros Spiliopoulos Lazaros Reppas Dimitrios Filippiadis Antonella Delvecchio Maria Conticchio Riccar do Memeo Riccardo Inchingolo | 2023 | World Journal of Gastroenterology2023，29，2： | 3 |
| 7 | Infrapopliteal Application of Sirolimus-eluting versus Bare Metal Stents for Critical Limb Ischemia: Analysis of Long-term Angiographic and Clinical Outcome显示文摘 | Dimitris Siablis Dimitris Karnabatidis Konstantinos Katsanos Athanasios Diamantopoulos Stavros Spiliopoulos George C. Kagadis John Tsolakis | 2009 | Journal of Vascular and Interventional Radiology2009，，： | 2 |
| 8 | Perioperative medical management and outcome following thymectomy for myasthenia gravis显示文摘 | Chevalley C Spiliopoulos A de Perrot M | 2001 | Can J Anaesth2001，48，5： | 1 |
| 9 | Periop- erativemedical management and outcome following thymectomy for myasthenia gravis显示文摘 | Chevalley C Spiliopoulos A de Perrot M | 2001 | Can J Anaesth2001，48，5： | 1 |
| 10 | Aromatic Polyamides and Polyimides Bearing Bulky ether Pendent Groups Derived from 1- aryloxy - 2, 4 - diaminobenzenes 显示文摘 | Spiliopoulos I K Mikroyaunidis J A | 1996 | Polymer1996，37，15： | 1 |
| 11 | Successful single lung transplantation after paraquat intoxication 显示文摘 | Walder B Bmndler M A Spiliopoulos A | 1997 | Transplanta- tion1997，64，5： | 1 |
| 12 | Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing显示文摘 | Dimitrios Karnabatidis Stavros Spiliopoulos Georgios Pastromas Panagiotis Kitrou Nikolaos Christeas Konstantinos Katsanos Dimitrios Siablis | 2014 | CardioVascular and Interventional Radiology2014，，： | 1 |
| 13 | Perioperative medical management and outcome following thymectomy for myasthenia gravis显示文摘 | Chevalley C Spiliopoulos A de Perrot M | 2001 | Can J Anaesth2001，48，： | 1 |
| 14 | Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease:the IDEAS randomized controlled trial显示文摘 | Siablis D Kitrou PM Spiliopoulos S | 2014 | JACC Cardiovasclnterv2014，7，9： | 1 |
| 15 | Overcoming ischemia in the diabetic foot:Minimally invasive treatment options显示文摘As the global burden of diabetes is rapidly increasing,the incidence of diabetic foot ulcers is continuously increasing as the mean age of the world population increases and the obesity epidemic advances.A significant percentage of diabetic foot ulcers are caused by mixed micro and macro-vascular dysfunction leading to impaired perfusion of foot tissue.Left untreated,chronic limb-threatening ischemia has a poor prognosis and is correlated with limb loss and increased mortality;prompt treatment is required.In this review,the diagnostic challenges in diabetic foot disease are discussed and available data on minimally invasive treatment options such as endovascular revascularization,stem cells,and gene therapy are examined. | Stavros Spiliopoulos Georgios Festas Ioannis Paraskevopoulos Martin Mariappan Elias Brountzos | 2021 | World Journal of Diabetes2021，12，12： | 1 |
| 16 | Feasibility of endovascular recanalization of occ|uded infrapopliteal drug-eluting stents显示文摘 | Spiliopoulos S Theodosiadou V Fragkos G | 2014 | J Endovasc Ther2014，21，： | 1 |
| 17 | Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty显示文摘 | Georgios Pastromas Stavros Spiliopoulos Konstantinos Katsanos Athanasios Diamantopoulos Panagiotis Kitrou Dimitrios Karnabatidis Dimitrios Siablis | 2013 | CardioVascular and Interventional Radiology2013，，： | 1 |
| 18 | Current evidence of drug-elution therapy for infrapopliteal arterial disease显示文摘New and sophisticated endovascular devices, such as drug-eluting stents(DES)and drug-coated balloons(DCB), provide targeted drug delivery to affected vessels. The invention of these devices has made it possible to address the reparative cascade of arterial wall injury following balloon angioplasty that results in restenosis. DESs were first used for the treatment of infrapopliteal lesions almost 20 years ago. More recently, however, DCB technology is being investigated to improve outcomes of endovascular below-the-knee arterial procedures, avoiding the need for a metallic scaffold. Today, level IA evidence supports the use of infrapopliteal DES for short to medium length lesions,although robust evidence that justifies the use of DCBs in this anatomical area is missing. This review summarizes and discusses all available data on infrapopliteal drug-elution devices and highlights the most promising future perspectives. | Stavros Spiliopoulos Nikiforos Vasiniotis Kamarinos Elias Brountzoss | 2019 | World Journal of Cardiology2019，11，1： | 1 |
| 19 | Platelet REsponsiveness to CLOpidogrel treatment after Peripheral endovascular procedures - The PRECLOP study: Clinical Impact and Optimal Cut-off Value of High On Treatment Platelet Reactivity显示文摘 | Stavros Spiliopoulos Georgios Pastromas Konstantinos Katsanos Panagiotis Kitrou Dimitrios Karnabatidis Dimitrios Siablis | 2013 | Journal of the American College of Cardiology2013，，： | 1 |
| 20 | Risk factors for acute lung injury after thoracic surgery for lung cancer显示文摘 | Licker M de Perrot M Spiliopoulos A | | 0，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员